US 11,918,647 B2
TfR selective binding compounds and related methods
Julien Hasler, Hoogstraten (BE); Julia Lynn Rutkowski, Bryn Mawr, PA (US); and Krzysztof Bartlomiej Wicher, Cambridge (GB)
Assigned to OSSIANIX, INC., Philadelphia, PA (US)
Filed by Ossianix, Inc., Philadelphia, PA (US)
Filed on Jun. 25, 2020, as Appl. No. 16/946,524.
Application 16/946,524 is a division of application No. 15/594,632, filed on May 14, 2017, granted, now 10,722,576.
Application 15/594,632 is a continuation of application No. PCT/US2015/060948, filed on Nov. 14, 2015.
Claims priority of provisional application 62/141,773, filed on Apr. 1, 2015.
Claims priority of provisional application 62/080,112, filed on Nov. 14, 2014.
Prior Publication US 2020/0316195 A1, Oct. 8, 2020
Int. Cl. C07K 14/705 (2006.01); A61K 39/395 (2006.01); C07K 16/40 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01); G01N 33/53 (2006.01)
CPC A61K 39/395 (2013.01) [C07K 16/2881 (2013.01); C07K 16/40 (2013.01); C07K 16/464 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C07K 2317/20 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/32 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/35 (2013.01); C07K 2317/52 (2013.01); C07K 2317/569 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01); C07K 2318/10 (2013.01); G01N 33/53 (2013.01)] 13 Claims
 
1. A transferrin receptor (TfR)-specific conjugate comprising a heterologous molecule operably linked to a TfR-specific binding moiety, wherein said TfR-specific binding moiety comprises a Type 2 VNAR domain capable of specifically binding to human TfR-1, wherein said moiety is capable of cross reacting with mouse TfR-1, and wherein said VNAR domain comprises or consists essentially of a VNAR scaffold with any one CDR1 peptide of SEQ ID NOS. 422, 423, 424, 426, 427, 429 or 434 in combination with any one CDR3 peptide of SEQ ID NOS. 189, 214, 215, 218, 226, 235, 237, 240 or 250.